2025-01-18 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**1. Performance vs. S&P 500 (VOO):**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  The provided data shows a cumulative return of 61.66% for MRK, significantly lagging behind the S&P 500's (VOO) cumulative return of 118.37%.  The difference is -56.7%, placing it at the 6.3rd percentile of its historical performance range relative to the S&P 500. This indicates underperformance compared to the broader market.  The provided alpha consistently shows negative values (-0.1), further supporting underperformance relative to the market benchmark.

**2. Recent Price Movement:**

* **Closing Price:** $97.92
* **5-Day Moving Average:** $99.87
* **20-Day Moving Average:** $99.48
* **60-Day Moving Average:** $100.25

The current price is below all three moving averages, suggesting a short-term downward trend.

**3. Technical Indicators and Expected Return:**

* **RSI:** 42.77 (Below 50, suggesting bearish momentum)
* **PPO:** 0.0132 (Positive, but very close to zero, indicating weak momentum)
* **Delta_Previous_Relative_Divergence:** -7.5% (Indicates a recent decrease in relative strength)
* **Expected Return (2+ years):** 96.5%  This represents the expected excess return over the S&P 500 with a long-term (2+ years) investment strategy.  However, the validity of this figure needs further analysis and consideration of risk. The 97.92 price being below recent moving averages suggests this expected return may need downward adjustment to account for the recent price decline.  This decline is not a *dramatic* drop, thus there is no need to characterize it as a "crash" or "sharp decline".


**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility in EPS and revenue.  While revenue generally shows an upward trend, EPS fluctuates.  There is a discrepancy in the data, showing duplicate entries for 2024-11-06. Clarification on this data is needed for a more accurate analysis.  A detailed analysis requires consistent, error-free data.

| Date       | EPS  | Revenue (B$) |
|------------|------|---------------|
| 2024-11-06 | 1.25 | 16.66         |
| 2024-08-05 | 2.15 | 16.11         |
| 2024-05-03 | 1.88 | 15.78         |
| 2023-11-03 | 1.87 | 15.96         |
| 2024-11-06 | 1.87 | 15.96         |


**5. Financial Information:**

The financial data shows generally strong revenue growth. Profit margins are high and relatively consistent, though there's some fluctuation. Return on Equity (ROE) is also volatile, indicating potential variability in profitability.  Further analysis is needed to understand the causes of this volatility, for instance, one time expenses or asset acquisition.

| Quarter    | Revenue (B$) | Profit Margin | Equity (B$) | ROE (%) |
|------------|---------------|---------------|-------------|---------|
| 2024-09-30 | 16.66         | 75.51%        | 44.50       | 7.09    |
| 2024-06-30 | 16.11         | 76.76%        | 43.58       | 12.52   |
| 2024-03-31 | 15.78         | 77.56%        | 40.36       | 11.80   |
| 2023-12-31 | 14.63         | 73.26%        | 37.58       | -3.26   |
| 2023-09-30 | 15.96         | 73.29%        | 41.25       | 11.50   |



**7. Overall Analysis:**

MRK has shown significant underperformance compared to the S&P 500 over the given period.  While the company demonstrates strong revenue and profit margins, the inconsistent earnings per share and ROE raise concerns.  Technical indicators suggest bearish momentum in the short term. The expected return, although positive, requires validation due to data inconsistencies and recent price movement.  A deeper dive into the financial statements, competitive landscape, and future growth prospects is crucial before making any investment decisions.  The discrepancy in the earnings data necessitates further investigation before forming concrete conclusions.

**8. Disclaimer:** This analysis is based on the provided data and is for informational purposes only.  It does not constitute financial advice.  Independent research and professional consultation are recommended before making any investment decisions.
